Fruquintinib becomes the first homegrown oncology drug approved in China for major indication
By Ajay V. Patil Tolerable safety profile of Chi-Med’s newly approved anti-VEGFR drug Elunate®Fruquintinib marked arrival of innovative homegrown oncology drugs in China for major indications like colorectal cancer (CRC). …
Read More